Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, first in human (FIH), randomised, double-blind, placebo-controlled, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of the recombinant respiratory syncytial virus vaccines (BARS13) when administered intramuscularly (IM) to healthy adult volunteers

Next Previous
Trial Profile

A Phase I, first in human (FIH), randomised, double-blind, placebo-controlled, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of the recombinant respiratory syncytial virus vaccines (BARS13) when administered intramuscularly (IM) to healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Respiratory syncytial virus vaccine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Advaccine (Suzhou) Biopharmaceuticals

Most Recent Events

  • 06 Sep 2019 Status changed from active, no longer recruiting to completed.
  • 13 May 2019 Status changed from recruiting to active, no longer recruiting.
  • 23 Jan 2019 According to Australian New Zealand Clinical Trials Registry record, recruitment completion is expected on 2/19/2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top